Evaluation of academic performance in Asian children aged 8 to 11 years with attention-deficit/hyperactivity disorder treated with atomoxetine hydrochloride.
Phase of Trial: Phase IV
Latest Information Update: 05 Jan 2010
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 16 Dec 2008 Status changed from active, no longer recruiting to completed.
- 10 Dec 2008 Planned end date changed from 1 Jan 2009 to 1 Nov 2008.
- 21 Sep 2008 Primary outcome changed as reported by ClinicalTrials.gov.